Immunic, Inc. (NASDAQ:IMUX) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET
Company Participants
Jessica Breu - Head of IR & Communications
Dr. Daniel Vitt - CEO and President
Glenn Whaley - CFO
Conference Call Participants
Caroline Pocher - Wedbush PacGrow
Liam Hiester - Piper Sandler
Matt Kaplan - Ladenberg Thalmann
Tom Smith - Leerink Partners
William Wood - B. Riley
Jessica Breu
Good morning, and welcome to Immunic's Third Quarter 2023 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call.
Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; as well as Glenn Whaley, our Chief Financial Officer. Please note that all participants will be in listen-only mode and this event is being recorded. [Operator Instructions]
Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation, and it undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results and these forward-looking statements.
I would now like to turn the call over to our CEO and President, Dr. Daniel Vitt, to begin the presentation. Daniel?
Dr. Daniel Vitt
Yes. Thank you, Jessica. I would also like to welcome everybody to today's earnings call. Earlier this morning, we announced our financial results for the third quarter ended September 30, 2023, in our press release and Form 10-Q. During the call today, we will walk through our third quarter 2023 and subsequent highlights, financial and operating results, as well as anticipated upcoming milestones. As Jessica noted, after the presentation, you will have the opportunity to ask questions.
Let's start with a review of our third quarter 2023 and subsequent highlights. I would like to begin with our vidofludimus calcium development program in multiple sclerosis. In August, we completed enrollment of our Phase 2 CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis or PMS. A total of 467 adult patients with primary MS or active or non-active secondary PMS were randomized to either 45 milligram daily doses of vidofludimus calcium or placebo. Patients were enrolled at more than 70 sites in North America, Western, Central and Eastern Europe.